The IDWP aims to promote and conduct educational activities and clinical investigations on all the topics concerning the diagnosis, the prophylaxis and the management of infectious complications following HSCT.
The mission of the IDWP is to share the experience and develop cooperative studies to increase education in the field of diagnosis, prophylaxis and treatment of infectious complications in HSCT patients.
IDWP Members continue their scientific and educational activity in the fields of: bacterial infections, viral infections, fungal infections including pneumocystis jiroveci infections, parasitic infections, vaccinations, protective environment and guidelines from the area of transplant infectious diseases.
Those wishing to initiate a study on behalf of IDWP are asked to fill in the corresponding document below. For submission or questions, please contact the IDWP Study Coordinator.
IDWP Publications List
Guidelines, Consensus Statements, and Position Papers
Due to fast spreading of SARS-CoV-2 a panel of experts of EBMT recommends the following guidelines for transplant units, recipients, and donors of hematopoietic cells. These guidelines will be updated when new information is obtained about COVID-19 epidemiology and clinical outcome.
Open calls to participate in a new study
The Infectious Diseases Working Party is currently overseeing the following study.
A case-control study on risk factors, timing, and PCR use, for pneumocystis pneumonia (PcP) after allogeneic HSCT: A non-interventional prospective study of the EBMT Infectious Diseases Working Party
Open until: indefinitely
This study aims to identify pre- and post-transplant factors associated with development of PcP after allogeneic HSCT and to report on:
- the methods used for the diagnosis of PcP in the EBMT centers.
- the timing of PcP after allogeneic HSCT.
- the severity of the disease and the outcome at 30 days and 90 days after the diagnosis of PcP.
- the specificities of the patients diagnosed only by PCR+ on BAL fluid, when compared to patients diagnosed by classical methods.
- the immune status of PcP patients.
- the prognostic factors to die from or with PcP, including co-infections.
Definition of PcP cases:
Any allogeneic HSCT recipient who, during the 1-year study period, underwent a BAL from the day of transplant, and whose BAL fluid was positive for PcP: either by qPCR alone, or positive cytology or IF, irrespectively of clinical presentation, imaging, co-infection and PcP treatment. Only first episode of PcP will be included (incident cases).
Due to the lack of standardization, qPCR on sputum only will not be taken in account for the diagnosis of PcP.
Inclusion criteria of the PcP cases:
- Allogeneic HSCT within the previous 24 months
- New case (first onset) of PcP documented in a BAL fluid, whatever the positive diagnostic test (cytology or IF or PCR) and whatever the presentation and treatment
- Any age
This is a multicentre prospective case-control study performed in volunteer EBMT centers on a prospective 12 months period.
For each recruiting center, the technic of qPCR will be collected, and the participation in an external quality control will be proposed to the center.
A short specific Med C will collect the data of the PcP cases and controls.
If interested in participating please contact firstname.lastname@example.org.